GET DAILY SIGNALSImageneBio (IMA): Repositioning as an Immunology and Inflammation Biotech
Key Takeaways
- ImageneBio, Inc. (IMA) is a clinical-stage biopharmaceutical company developing therapies for immunological, autoimmune, and inflammatory (I&I) diseases.
- The company was formerly known as Ikena Oncology and rebranded as ImageneBio in July 2025 to reflect its pivot away from oncology.
- Its lead product candidate, IMG-007, is a non-depleting anti-OX40 monoclonal antibody in Phase 1b/2a clinical development.
- ImageneBio is headquartered in San Diego, California, and its shares trade on the Nasdaq Capital Market.
- As a clinical-stage company with no approved products, ImageneBio generates minimal revenue and operates at a loss while advancing its pipeline.
Company Background
ImageneBio, Inc. focuses on creating new treatments for patients with immunological, autoimmune, and inflammatory conditions. I follow IMA as a small-cap biotech story that hinges largely on one lead asset, where trial outcomes can shift the outlook noticeably. Like many peers at this stage, the company's value rests more on its development pipeline than on current sales or profits.
Strategic Shift and Pipeline
Based in San Diego, California, the company previously operated as Ikena Oncology with a cancer-focused approach. The July 2025 name change to ImageneBio marked a clear move into the I&I space. Its main asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody now in Phase 1b/2a trials. This antibody targets the OX40 receptor on activated T cells to help modulate immune responses in inflammatory diseases without depleting the cells themselves. With no marketed products yet, the company relies on equity raises and existing cash to fund studies aimed at eventual regulatory approval.
Why I Watch IMA
Interest in IMA centers on the potential of IMG-007 within a sizable immunology market. A differentiated mechanism like non-depleting OX40 blockade could draw partnership or acquisition interest from larger players if data prove strong. The focused strategy on a single program sharpens resources but also ties outcomes closely to that asset's progress. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Risks to Consider
Clinical-stage biotech investing involves real uncertainty. IMG-007 still needs to show safety and efficacy in later trials, and many candidates do not succeed. A single-program focus means disappointing results could weigh heavily on the company. Other factors include competition from well-funded pharmaceutical firms, possible regulatory hurdles, ongoing financing needs, and the volatility typical of small development-stage names.
Integrating AI Tools in Research
Tickeron's AI Screener helps me quickly scan for ideas across sectors using technical indicators, fundamentals, volatility measures, trends, and AI-generated signals. For a name like ImageneBio, it offers a practical way to apply custom filters and surface comparable opportunities without sifting through thousands of listings manually.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IMA in upward trend: price may jump up because it broke its lower Bollinger Band on October 08, 2026
IMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 40 cases where IMA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMA's RSI Indicator exited the oversold zone, 28 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 68 cases where IMA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for IMA just turned positive on October 23, 2026. Looking at past instances where IMA's MACD turned positive, the stock continued to rise in 44 of 50 cases over the following month. The odds of a continued upward trend are 88%.
Following a +4.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMA advanced for three days, in 172 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMA as a result. In 91 of 112 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for IMA entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.331) is normal, around the industry mean (3.498). P/E Ratio (-0.876) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (35.971) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. IMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement